Crossmark

Transcriptomic analysis reveals molecular alterations and candidate transcriptomic features associated with dapagliflozin treatment in patients with type 2 diabetes mellitus

Crossref DOI link: https://doi.org/10.1038/s41598-026-65879-6

Published Online: 2026-08-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhong, Di

Jiang, Zhaohui

Ren, Tingting
License Information

Text and Data Mining valid from 2026-08-07

Version of Record valid from 2026-09-22
More Information

Article History

Received: 1 June 2026

Accepted: 4 August 2026

First Online: 7 August 2026

Declarations

Competing interests: The authors declare no competing interests.

Ethical approval: This study was conducted in accordance with the Declaration of Helsinki and approved by the Medical Ethics Committee of The First People’s Hospital of Guiyang (Approval No. 2025-S169). Written informed consent was obtained from all patients prior to clinical sample collection for experimental analysis, ensuring compliance with ethical standards and respect for patient rights and autonomy.

Consent to participate: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below